Quantitative measurement of eye and head movements for the diagnosis of traumatic brain injury and neurodegeneration.

This technology is a method to treat Alzheimer’s disease by reducing the level of the cellular biomarker APP-C99.

This technology is a mechanism for treating brain disorders resulting from Group A Streptococcus infection including encephalitis by targeting a serum cytokine biomarker IL-17A.

This technology is NeuroScore AI, an automated AI program that can be used to calculate Alzheimer’s Disease risk score by transcribing audio files from standardized cognitive testing.

This technology is a hybrid configuration of multi-coils and radiofrequency magnets that can improve clinical magnetic resonance imaging (MRI) quality.

This technology is a dual-head MRI system equipped with local shimming capabilities for simultaneous functional imaging of two adjacent subjects, facilitating the study of interpersonal interactions and social connections.

This technology is a method of using metabolic profiling-related biomarkers to identify newborns or infants with autism spectrum disorder for early intervention.

This technology is an in vivo tool using focused ultrasound (FUS) with microbubbles to induce blood-brain barrier opening (BBBO) and increase serum extracellular vesicle (EV) levels.

This technology includes two chemical compounds that are phosphodiesterase type 5 (PDE5) inhibitors with a benzonaphthyridine derivative chemical scaffold that has not previously been used to treat Alzheimer’s disease or other conditions involving phosphodiesterase PDE5 function.

This technology uses peptides secreted by engineered bacteria to reduce virulence of Fusobacterium nucleatum.

This technology is a fully integrated holographic microscope system capable of simultaneous, high-resolution imaging and precise stimulation of 3D neuronal circuits using optogenetics.

This technology is an enzyme that is involved in synthesizing a precursor to bis(monoacylglycero)phosphate (BMP) and can be used to modulate BMP levels and treat BMP-related disorders.

This technology is a deep-contrast AI-enabled algorithm to predict blood-brain barrier (BBB) openings from T1 MRI sequences using low doses of gadolinium-based contrast agents (GBCA).

This technology is a web-based AI system which uses real-time speaker diarization, transcription, and natural language processing (NLP) to optimize and support mental health care services.

This technology describes caspase-2 inhibitors for the treatment of neurodegenerative diseases such as Alzheimer’s disease.